Study of LRRK2 gene and brain scans in Parkinson's disease
Part of Brain & nervous system clinical trials.
This study looks at a genetic marker called LRRK2 that might help identify different types of Parkinson's. You'll have blood tests and an MRI scan to help researchers understand this. It could lead to better treatments and care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 30 and 80 years old
- You must have a confirmed Parkinson's disease diagnosis (by a doctor using standard criteria)
- Your Parkinson's should be in early to moderate stages (Hoehn and Yahr stage 1-3) — not too advanced
- You may be included either if your Parkinson's is linked to the LRRK2 gene or if it's the common form (sporadic). You'll have genetic testing to find out
- You must be able to have an MRI scan (no metal implants, no severe claustrophobia)
- You must not have other active neurological, autoimmune, or cancer conditions. Also no recent infections or certain medications (like steroids or NSAIDs for over a week) in the past 12 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how a protein called alpha-synuclein spreads in Parkinson's disease by checking blood and brain scans. It aims to understand why some people develop Parkinson's and to find clues that could lead to better treatments.
This study uses brain scans to understand Parkinson's disease. It compares people with Parkinson's to healthy volunteers to learn how the brain changes.
This research study uses advanced MRI brain imaging to understand how a specific gene mutation (LRRK2) affects certain brain chemicals in people with Parkinson's disease. The goal is to learn more about how this genetic form of Parkinson's works, which could help develop better treatments.
This study is a registry that collects information from people with Parkinson’s who have specific LRRK2 gene changes. It helps researchers understand how this genetic form of Parkinson’s behaves over time.
This trial studies genetic and biological samples from people with Parkinson's disease, their at-risk relatives, and healthy volunteers. It aims to find biomarkers that could help with earlier diagnosis and better treatments.
This study builds a genetics “registry” of people diagnosed with Parkinson’s disease who agree to genetic testing. Your information may help researchers understand why Parkinson’s happens and improve future treatments.
Hear when a new Parkinsons Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.